Congress moves to strip patents from pricey drugs, opening door to generics

What it does

This bill creates a federal process to identify brand-name drugs with 'excessive' prices—defined primarily by comparing U.S. prices to those in Canada, the UK, Germany, France, and Japan. When a drug is flagged as excessively priced, the government can strip its patent protections and grant open licenses to generic and biosimilar manufacturers, who pay a 'reasonable royalty' to the original patent holder. The bill also requires drug makers to report detailed pricing and R&D cost data annually, establishes a public database of flagged drugs, and imposes civil penalties on manufacturers who fail to report or provide false information.

Why we flagged it

The bill's core mechanism is a government-administered price-review system that can strip patent exclusivity from branded drugs deemed excessively priced and grant compulsory licenses to competitors. This is a direct intervention in pharmaceutical pricing and intellectual property, not a routine regulatory adjustment.

What the text implies

• The 'reasonable royalty' standard is set by the Secretary and may be contested, creating ongoing litigation risk and uncertainty for generic manufacturers about their actual cost of entry.
• International reference pricing (Canada, UK, Germany, France, Japan) may not reflect actual manufacturing costs or market conditions in those countries, potentially setting royalty rates below sustainable levels for innovation.
• The bill does not explicitly address how the Secretary will handle drugs with limited international pricing data or orphan drugs serving small populations, creating potential gaps in the excessive-price determination process.
• Civil penalties for non-reporting (0.5–1% of annual drug revenue per day late) could incentivize manufacturers to challenge determinations in court rather than comply, delaying generic entry.
• The anticompetitive-behavior prohibition in Section 7 is vague and references only FTC Act Section 5, leaving unclear what conduct is prohibited and who enforces it.

Who it affects

Ordinary citizens stand to benefit from lower drug prices through generic competition and increased transparency about pricing decisions. The mechanism directly targets high-priced medications and creates a pathway for cheaper alternatives, which reduces out-of-pocket costs and improves access for uninsured and underinsured patients. The public database and reporting requirements also increase accountability and visibility into pharmaceutical pricing practices.

Who stands to gain

• generic drug manufacturers
• biosimilar manufacturers
• pharmacy benefit managers (PBMs)
• health insurance companies
• government health programs (Medicare, Medicaid)

Named in the bill

FDA, HHS Secretary, Pfizer (PFE), Bristol Myers Squibb (BMY), DaVita (DVA), Guardant Health (GH), West Pharmaceutical Services (WST), National Institutes of Health (NIH), Federal Trade Commission (FTC), Canada, United Kingdom, Germany — and 2 more

Where it stands

7 cosponsors: 7 Democrats.

• May 20, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• May 20, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $840,000 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Bernie Sanders, the sponsor, reported $-5,000 in PAC receipts in the 2026 cycle.

• Grifols Shared Services North America Inc — $840,000 on 2 filings

Lobbying Disclosure Act filings through Jul 17, 2026. A filing shows who paid to lobby on a bill it names, not what changed.